383 related articles for article (PubMed ID: 12894198)
1. Biopharmaceutical benchmarks--2003.
Walsh G
Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
[No Abstract] [Full Text] [Related]
2. The biotech drug market.
Lawrence S
Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
[No Abstract] [Full Text] [Related]
3. Editorial: biopharmaceutical technologies.
Jungbauer A
Biotechnol J; 2007 Jun; 2(6):647. PubMed ID: 17570696
[No Abstract] [Full Text] [Related]
4. Biopharmaceuticals: recent approvals and likely directions.
Walsh G
Trends Biotechnol; 2005 Nov; 23(11):553-8. PubMed ID: 16051388
[TBL] [Abstract][Full Text] [Related]
5. Biopharmaceutical benchmarks 2006.
Walsh G
Nat Biotechnol; 2006 Jul; 24(7):769-76. PubMed ID: 16841057
[TBL] [Abstract][Full Text] [Related]
6. Biopharmaceutical benchmarks 2010.
Walsh G
Nat Biotechnol; 2010 Sep; 28(9):917-24. PubMed ID: 20829826
[No Abstract] [Full Text] [Related]
7. Biopharmaceutical statistics in a pharmaceutical regulated environment: past, present, and future.
Segreti AC; Leung HM; Koch GG; Davis RL; Mohberg NR; Peace KE
J Biopharm Stat; 2001 Nov; 11(4):347-72. PubMed ID: 12018784
[TBL] [Abstract][Full Text] [Related]
8. 2004 approvals: the demise of the blockbuster?
Frantz S
Nat Rev Drug Discov; 2005 Feb; 4(2):93-4. PubMed ID: 15756752
[No Abstract] [Full Text] [Related]
9. Opinion: New Jersey is still the world's cure corridor.
Franks B
N J Med; 2003 Nov; 100(11):60, 59. PubMed ID: 14679607
[No Abstract] [Full Text] [Related]
10. [Fewer new drugs from drug industry].
Reikvam A
Tidsskr Nor Laegeforen; 2007 Nov; 127(23):3106-7. PubMed ID: 18049505
[No Abstract] [Full Text] [Related]
11. New drug development in the United States from 1963 to 1999.
Dimasi JA
Clin Pharmacol Ther; 2001 May; 69(5):286-96. PubMed ID: 11371996
[No Abstract] [Full Text] [Related]
12. Key factors in the rising cost of new drug discovery and development.
Dickson M; Gagnon JP
Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
[No Abstract] [Full Text] [Related]
13. Pipelines turn to biotech.
Lawrence S
Nat Biotechnol; 2007 Dec; 25(12):1342. PubMed ID: 18066015
[No Abstract] [Full Text] [Related]
14. Biotech drug market steadily expands.
Lawrence S
Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
[No Abstract] [Full Text] [Related]
15. Raising the game.
Nat Biotechnol; 2008 Feb; 26(2):137. PubMed ID: 18259155
[No Abstract] [Full Text] [Related]
16. Trends in development and approval times for new therapeutics in the United States.
Reichert JM
Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576
[TBL] [Abstract][Full Text] [Related]
17. Drug discovery alliances.
Jones A; Clifford L
Nat Rev Drug Discov; 2005 Oct; 4(10):807-8. PubMed ID: 16237845
[No Abstract] [Full Text] [Related]
18. Security market reaction to FDA fast track designations.
Anderson CW; Zhang Y
J Health Care Finance; 2010; 37(2):27-48. PubMed ID: 21294437
[TBL] [Abstract][Full Text] [Related]
19. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
20. Private company profiles.
Nat Biotechnol; 2002 Jul; 20 Suppl():BE15-21. PubMed ID: 12089572
[No Abstract] [Full Text] [Related]
[Next] [New Search]
